Laurie D. Stelzer
2017
In 2017, Laurie D. Stelzer earned a total compensation of $1.8M as Senior Vice President and Chief Financial Officer at Halozyme Therapeutics, a 3% decrease compared to previous year.
Compensation breakdown
Non-Equity Incentive Plan | $282,563 |
---|---|
Option Awards | $550,000 |
Salary | $452,000 |
Stock Awards | $550,006 |
Other | $9,210 |
Total | $1,843,779 |
Stelzer received $550K in stock awards, accounting for 30% of the total pay in 2017.
Stelzer also received $282.6K in non-equity incentive plan, $550K in option awards, $452K in salary and $9.2K in other compensation.
Rankings
In 2017, Laurie D. Stelzer's compensation ranked 5,896th out of 14,666 executives tracked by ExecPay. In other words, Stelzer earned more than 59.8% of executives.
Classification | Ranking | Percentile |
---|---|---|
All | 5,896 | 60th |
Manufacturing | 2,149 | 63rd |
Chemicals And Allied Products | 671 | 68th |
Drugs | 519 | 70th |
Biological Products, Except Diagnostic Substances | 93 | 70th |
Stelzer's colleagues
We found four more compensation records of executives who worked with Laurie D. Stelzer at Halozyme Therapeutics in 2017.